The prognosis of pancreati cancer is still poor in spite of advance in surgical treatment and parasurgical adjuvant management. Eighteen patients with histologically confirmed locally advanced adenocarcinoma of the pancreas were received radiation(5000cGy)+5-FU. Patients were treated with 5-FU 200 mg/m IV bolus, 1 hour before irradiation each day. In some patients, within 30 minutes after radiotherapy, hyperthemia was added to above protocol two times weekly. Median survival of total patients was 9.5months. Median survival with RT+ 5-FU was 12.7months from the date of treatment. Median survival with hyperthemia added group was 7.6months, but the survival dif- ference was not significant statistically. The side effects were acceptable. There were no episodes of any life threatening toxicities.